The global swab and viral transport medium market is estimated to exhibit a CAGR of 6.1 % over the forecast period 2022-2030, according to a new research by Future Market Insights (FMI).
An upswing in the sales of critical equipment with respect to collection and transportation of samples is currently underway. This has escalated the production of swab and viral transport medium, thereby driving the market.
To detect the viral RNA in human body; nasopharyngeal swab and deep nasal swab techniques are being used. The overall market is primarily driven by increased rate of flu in various regions. As per CDC, 2019-20 season has witnessed close to 20 Mn cases of influenza in the U.S. with 280,000 hospitalizations as on Feb 15, 2020.
For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-11195
At the same time, efforts taken by respective governments to increase awareness about flu, coupled with initiatives undertaken by World Health Organization (WHO), Global Alliance for Vaccines and Immunization (GAVI), The Pan American Health Organization (PAHO), etc. are expected to drive the market.
“Expanded Program on Immunization” is one the initiatives taken by PAHO at the pan American level. In Jan 2020, GAVI, at the behest of MSF (Doctors without Borders) bulk brought cheaper pneumococcal vaccine for around 55 Mn children. The initiatives mentioned above would be taken up in the forecast period as well. That will certainly ask for more swab and viral transformation motion to be in place.
Key Takeaways from Swab and Viral Transport Medium Market Study
For Information On The Research Approach Used In The Report, Request TOC@ https://www.futuremarketinsights.com/toc/rep-gb-11195 New Product Launches: Key Strategic Focus Area of Swab and Viral Transport Medium Market Players
New product launches/approvals and governments’ support are raising the bar for competition amongst market players. Numerous organizations are focusing on new product launches for diagnostic test especially for coronavirus and influenza. For Instance, DiaSorin, a prominent manufacturer of swabs specifies NP swabs in 3 ml of Copan Universal Transport Media (UTM) or BD Viral Transport Media. In 2019, MWE launched ∑-VCM transport device, to enable the collection, transport and preservation of viruses.
The other players included as a part of market study include McKesson Corporation, Cardinal Health Inc., Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Quidel Corporation, COPAN Diagnostics Inc., VIRCELL S.L., Deltalab, and Medical Wire & Equipment (MWE).
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us: Future Market Insights, Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A, Jumeirah Lakes Towers, Dubai, United Arab Emirates LinkedIn| Twitter| Blogs For Sales Enquiries: sales@futuremarketinsights.com Website: https://www.futuremarketinsights.com
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings. The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings. The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2022 PHARMIWEB.COM LIMITED, rights reserved by the relevant holders.
You are leaving PharmiWeb.com
Disclaimer: You are now leaving PharmiWeb.com website and are going to a website that is not operated by us. We are not responsible for the content or availability of linked sites.
ABOUT THIRD PARTY LINKS ON OUR SITE
PharmiWeb.com offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links you will leave the PharmiWeb.com website and will be redirected to another site. These sites are not under the control of PharmiWeb.com.
PharmiWeb.com is not responsible for the content of linked third party websites. We are not an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. We suggest that you always verify the information obtained from linked websites before acting upon this information.
Also, please be aware that the security and privacy policies on these sites may be different than PharmiWeb.com policies, so please read third party privacy and security policies closely.
If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly.